MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Clinical trial NCT04110301 · RECRUITING

Trial details

NCT number: NCT04110301
Sponsor: Beijing Mabworks Biotech Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Follicular Lymphoma and Marginal Zone Lymphoma

Start date: 2019-11-28
Primary completion: 2024-01-09
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.